Clinical Scorecard: Evaluating the Safety and Effectiveness of Serenoa repens Extract in Treating Chronic Prostatitis/Chronic Pelvic Pain Syndrome: Results from a Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

At a Glance

Key Highlights

• Multicenter, randomized, double-blind, placebo-controlled phase 4 trial with 226 male patients
• Daily treatment with 320 mg Serenoa repens extract (160 mg BID) versus placebo over 12 weeks
• Primary endpoint: change in NIH-CPSI total score; clinical response defined as ≥6-point improvement

Guideline-Based Recommendations

Diagnosis

• Diagnosis based on NIH criteria for CP/CPPS with NIH-CPSI score >10 and pain score ≥4
• Exclude urinary tract infection, acute epididymitis, prostate cancer, and other confounding conditions
• Use NIH-CPSI and IIEF-5 questionnaires, physical exam, laboratory tests, prostate ultrasound, and standardized four-glass test

Management

• Serenoa repens extract 320 mg daily (160 mg BID) recommended as a phytotherapeutic option for CP/CPPS
• Avoid concurrent use of antibiotics, NSAIDs, α-adrenergic blockers, bioflavonoids, and other phytotherapeutics during treatment
• Treatment duration of 12 weeks with regular follow-up assessments

Monitoring & Follow-up

• Assess symptom changes using NIH-CPSI total and domain scores at baseline and weeks 2, 4, 8, and 12
• Evaluate sexual function with IIEF-5 questionnaire
• Monitor for adverse events throughout treatment

Risks

• Few adverse events reported with Serenoa repens extract use
• Exclude patients with liver or kidney insufficiency or allergies to study drug
• Contraindicated in patients with active infections or other excluded comorbidities

Patient & Prescribing Data

Men aged 18–50 years with clinically and laboratory diagnosed CP/CPPS and NIH-CPSI >10

Serenoa repens extract showed a statistically significant reduction in NIH-CPSI scores compared to placebo, indicating symptom improvement with good safety profile

Clinical Best Practices

• Perform thorough baseline assessment including NIH-CPSI and IIEF-5 scoring before initiating treatment
• Ensure exclusion of confounding infections and comorbidities prior to prescribing Serenoa repens extract
• Maintain double-blind conditions in clinical trials to reduce bias
• Use a 12-week treatment duration with regular symptom monitoring to evaluate efficacy
• Educate patients on avoiding other prostatitis treatments during study period to isolate effects of Serenoa repens extract

References

• National Institutes of Health classification of prostatitis
• NIH Chronic Prostatitis Symptom Index (NIH-CPSI)
• International Index of Erectile Function 5 (IIEF-5)
• Nickel et al. clinical response criteria for CP/CPPS
• Phase 3 study of Cernilton in CP/CPPS